Abstract
The combined use of a photosensitizing agent, light and dioxygen for the treatment of diseases has become known as photodynamic therapy (PDT) and was first discovered more than one hundred years ago. Over the years, PDT has proven its potential for the treatment of malignant and non-malignant lesions in addition to classical cancer therapy in numerous clinical studies, but application as a routine method is still limited. In this review, the development of modern PDT since the beginning of the twentieth century is briefly portrayed. The underlying mechanisms of phototoxicity are explained, and the requirements for ideal photosensitizers (PS) are underlined. Selected PS are introduced and examples of some of the many attempts made at the optimization of PDT by developing new PS with improved chemical and phototoxic properties, are reviewed. Promising 3rd generation PS are introduced and newer approaches to increasing tumor selectivity and efficacy of PDT, such as with nanoparticles, are discussed.
Keywords: Photodynamic therapy, photosensitizers, upconversion nanoparticles.
Current Pharmaceutical Design
Title:Photosensitizers for Photodynamic Therapy: Photochemistry in the Service of Oncology
Volume: 22 Issue: 46
Author(s): Carsten Lange and Patrick J. Bednarski
Affiliation:
Keywords: Photodynamic therapy, photosensitizers, upconversion nanoparticles.
Abstract: The combined use of a photosensitizing agent, light and dioxygen for the treatment of diseases has become known as photodynamic therapy (PDT) and was first discovered more than one hundred years ago. Over the years, PDT has proven its potential for the treatment of malignant and non-malignant lesions in addition to classical cancer therapy in numerous clinical studies, but application as a routine method is still limited. In this review, the development of modern PDT since the beginning of the twentieth century is briefly portrayed. The underlying mechanisms of phototoxicity are explained, and the requirements for ideal photosensitizers (PS) are underlined. Selected PS are introduced and examples of some of the many attempts made at the optimization of PDT by developing new PS with improved chemical and phototoxic properties, are reviewed. Promising 3rd generation PS are introduced and newer approaches to increasing tumor selectivity and efficacy of PDT, such as with nanoparticles, are discussed.
Export Options
About this article
Cite this article as:
Lange Carsten and Bednarski J. Patrick, Photosensitizers for Photodynamic Therapy: Photochemistry in the Service of Oncology, Current Pharmaceutical Design 2016; 22 (46) . https://dx.doi.org/10.2174/1381612822666161124155344
DOI https://dx.doi.org/10.2174/1381612822666161124155344 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Homocysteine and Hyperhomocysteinaemia
Current Medicinal Chemistry The Role for Oxidative Stress in Aberrant DNA Methylation in Alzheimer’s Disease
Current Alzheimer Research The role of NADPH Oxidase in Vascular Disease – Hypertension, Atherosclerosis & Stroke
Current Pharmaceutical Design Virally Encoded G Protein-Coupled Receptors: Targets for Potentially Innovative Anti-Viral Drug Development
Current Drug Targets Proliferative Retinopathies: Animal Models and Therapeutic Opportunities
Current Neurovascular Research Autoimmune Diseases and Atherosclerosis: The Inflammatory Connection
Current Immunology Reviews (Discontinued) Circulatory Syndrome: An Evolution of the Metabolic Syndrome Concept!
Current Cardiology Reviews Animal Models in Neurology: Drawbacks and Opportunities
Current Pharmaceutical Design Lipoproteins, Stroke and Statins
Current Vascular Pharmacology The Roles of MicroRNAs in Atherosclerosis
Current Medicinal Chemistry Pleiotropic Effects of the Rho-kinase Inhibitor Fasudil After Subarachnoid Hemorrhage: A Review of Preclinical and Clinical Studies
Current Vascular Pharmacology Effects of <I>Gentiana lutea</I> Root on Vascular Diseases
Current Vascular Pharmacology The Role of Endothelial Dysfunction in Aortic Aneurysms
Current Pharmaceutical Design Why are People with “Poor Lung Function” At Increased Atherothrombotic Risk?A Critical Review with Potential Therapeutic Indications
Current Vascular Pharmacology Protein kinases and the Hypoxia-Inducible Factor-1, two switches in angiogenesis
Current Pharmaceutical Design Advances in the Treatment of Neurodegenerative Disorders Employing Nanoparticles
Recent Patents on Drug Delivery & Formulation Further Issues with New Oral Anticoagulants
Current Pharmaceutical Design Matrix Metalloproteinases as Drug Targets in Preeclampsia
Current Drug Targets Von Willebrand Factor: Drug and Drug Target
Cardiovascular & Hematological Disorders-Drug Targets Design, Synthesis, and Biological Evaluation of Novel Tetramethylpyrazine- nitrone Derivatives as Antioxidants
Letters in Drug Design & Discovery